Two Decades of PARP Inhibitor Synthetic Lethality in Cancer
This article reviews the twenty-year impact of PARP inhibitor synthetic lethality in cancer treatment, originating from two landmark 2005 Nature papers. These studies demonstrated that PARP inhibitors selectively kill cells deficient in BRCA1 or BRCA2 tumor suppressor genes, leading to the first clinically approved targeted therapy based on a germline biomarker. Recognized as a top cancer discovery of the twenty-first century, this approach has significantly improved survival and quality of life for patients with specific breast, ovarian, prostate, and pancreatic cancers. The findings transformed germline BRCA testing from a risk assessment tool into a companion diagnostic for therapy selection. Furthermore, the success of the BRCA-PARP synthetic lethal concept has highlighted functional redundancies in tumor cells, stimulating broader research into other tumour-specific synthetic lethal effects. The authors distill key learnings from the past two decades, discussing mechanisms of sensitivity and resistance, and exploring how this foundational biological discovery has been leveraged for patient benefit, extending the therapeutic landscape beyond initial BRCA-mutant indications.
Wire timeline
Two Decades of PARP Inhibitor Synthetic Lethality in Cancer
This article reviews the twenty-year impact of PARP inhibitor synthetic lethality in cancer treatment, originating from two landmark 2005 Nature papers. These studies demonstrated that PARP inhibitors selectively kill cells deficient in BRCA1 or BRCA2 tumor suppressor genes, leading to the first clinically approved targeted therapy based on a germline biomarker. Recognized as a top cancer discovery of the twenty-first century, this approach has significantly improved survival and quality of life for patients with specific breast, ovarian, prostate, and pancreatic cancers. The findings transformed germline BRCA testing from a risk assessment tool into a companion diagnostic for therapy selection. Furthermore, the success of the BRCA-PARP synthetic lethal concept has highlighted functional redundancies in tumor cells, stimulating broader research into other tumour-specific synthetic lethal effects. The authors distill key learnings from the past two decades, discussing mechanisms of sensitivity and resistance, and exploring how this foundational biological discovery has been leveraged for patient benefit, extending the therapeutic landscape beyond initial BRCA-mutant indications.
Nature